---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-007763"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:12:52.951212+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AgeX borrows $10M from Juvenescence, lends to Serina; Dr. West resigns from board

## Summary
- Entered $10M secured convertible note with Juvenescence; proceeds used to purchase $10M Serina note.
- Juvenescence note matures March 2026; 7% origination fee; convertible into AgeX common stock after merger or March 2024.
- Dr. Michael D. West resigned from AgeX board but remains CEO; expected to transition to CEO of subsidiary Reverse Bio after spinoff.
- Potential merger with Serina and spinoff of Reverse Bio are under consideration but no definitive agreements executed yet.

## SEC filing metadata
- accession: 0001493152-23-007763
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/0001493152-23-007763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-007763
- JSON: https://secwatch.observer/filing/0001493152-23-007763.json
- Plain text: https://secwatch.observer/filing/0001493152-23-007763.txt

## Key facts
- Debt Financings
  Serina Therapeutics, Inc. incurred convertible notes of $10,000,000 with Juvenescence Limited at origination fee in an amount equal to 7% of the loan funds disbursed to AgeX maturing March 13, 2026.
  - Instrument: convertible notes
  - Principal: $10,000,000
  - Counterparty: Juvenescence Limited
  - Rate: origination fee in an amount equal to 7% of the loan funds disbursed to AgeX
  - Maturity: March 13, 2026
  - Event: incurrence
  source text: (“ AgeX ”) and Juvenescence Limited (“ Juvenescence ”) entered into a Secured Convertible Promissory Note (the “ Juvenescence Note ”) pursuant to which Juvenescence
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/0001493152-23-007763-index.htm
- Executive change
  Dr. Michael D. West resigned as Director at Serina Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On March 9, 2023, Dr. Michael D. West resigned from AgeX’s Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/0001493152-23-007763-index.htm
- Material Agreements
  Serina Therapeutics, Inc. entered into Convertible Note Purchase Agreement with AgeX Therapeutics, Inc. valued at $10,000,000 (effective 2023-03-15).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: AgeX Therapeutics, Inc.
  - Value: $10,000,000
  - Effective: 2023-03-15
  source text: Serina Therapeutics Inc., an Alabama corporation (“ Serina ”) to AgeX on March 15, 2023, pursuant to the terms of a Convertible Note Purchase Agreement, dated March 15, 2023 (the “ Serina Note Purchase Agreement ”), between AgeX and Serina.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/0001493152-23-007763-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.